Get all premium features to the best stock analysis tool

Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer Conference

HENDERSON, Nev., March 26, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the presentation of an abstract at the European Lung Cancer Conference (ELCC) in Copenhagen, Denmark this week.

Volition Announces Detection of Over 95% of Early-Stage Cancers

Blinded validation cohort achieves over 95% sensitivity for stage I & II cancers with 95% specificity Capture-Seq™ Targets $36 Billion TAM in Early Cancer Detection and MRD. HENDERSON, Nev.

Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA

Targets $36 Billion TAM in Early Cancer Detection and MRD. Company in active discussions with global diagnostic leaders to accelerate commercialization.

Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems

HENDERSON, Nev., March 6, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the completion of all validation and verification of the chemiluminescent immunoassay (ChLIA) version of its Nu.Q® Vet Cancer Test with Fujifilm Vet Systems Co. Ltd ("Fujifilm Vet Systems") in Japan, allowing use of full automation rather than manual plates in central laboratories.